These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 9867152)
21. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer. Weiss K; Köck HH; Atefie K; Sinzinger H Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421 [No Abstract] [Full Text] [Related]
22. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Anderson P; Nuñez R Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921 [TBL] [Abstract][Full Text] [Related]
23. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP. Yousefnia H; Zolghadri S Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757 [TBL] [Abstract][Full Text] [Related]
24. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Serafini AN Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381 [TBL] [Abstract][Full Text] [Related]
25. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221 [TBL] [Abstract][Full Text] [Related]
26. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP. Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610 [TBL] [Abstract][Full Text] [Related]
27. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654 [TBL] [Abstract][Full Text] [Related]
28. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Sandeman TF; Budd RS; Martin JJ Clin Oncol (R Coll Radiol); 1992 May; 4(3):160-4. PubMed ID: 1375094 [TBL] [Abstract][Full Text] [Related]
29. [Three-dimensional dose calculation of 153Sm-EDTMP in treating bone metastasis--comparison of Monte Carlo and S value calculation methods]. Chen LX; Liu XW; Gan F; Tang Q; You RA; Zhang WG; Fan W Ai Zheng; 2006 Nov; 25(11):1399-405. PubMed ID: 17094909 [TBL] [Abstract][Full Text] [Related]
30. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117 [TBL] [Abstract][Full Text] [Related]
31. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Maini CL; Bergomi S; Romano L; Sciuto R Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241 [TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Dolezal J; Vizda J; Odrazka K Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733 [TBL] [Abstract][Full Text] [Related]
33. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats]. Shi B; Fu Z; Lei XH Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Louw WK; Dormehl IC; van Rensburg AJ; Hugo N; Alberts AS; Forsyth OE; Beverley G; Sweetlove MA; Marais J; Lötter MG; van Aswegen A Nucl Med Biol; 1996 Nov; 23(8):935-40. PubMed ID: 9004281 [TBL] [Abstract][Full Text] [Related]
35. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases. Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829 [TBL] [Abstract][Full Text] [Related]
36. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431 [TBL] [Abstract][Full Text] [Related]
37. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases]. Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908 [TBL] [Abstract][Full Text] [Related]
38. Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients. Parlak Y; Gumuser G; Sayit E Radiat Prot Dosimetry; 2015 Mar; 163(4):468-72. PubMed ID: 25063786 [TBL] [Abstract][Full Text] [Related]
39. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919 [TBL] [Abstract][Full Text] [Related]
40. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Rösch F; Herzog H; Plag C; Neumaier B; Braun U; Müller-Gärtner HW; Stöcklin G Eur J Nucl Med; 1996 Aug; 23(8):958-66. PubMed ID: 8753686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]